Trial Profile
A Phase III, Comparative Study for the Efficacy and Safety of Bilastine 20 mg Versus Cetirizine 10 mg and Placebo in the Treatment of Perennial Allergic Rhinitis During 4 Weeks, Followed by a Long-term Safety Extension With Bilastine 20 mg.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Mar 2012
Price :
$35
*
At a glance
- Drugs Bilastine (Primary) ; Cetirizine
- Indications Perennial allergic rhinitis
- Focus Adverse reactions; Therapeutic Use
- 13 Nov 2011 Results published in the Current Medical Research and Opinion.
- 24 May 2010 New trial record